Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis

JCI Insight

Volumn 1, Issue 20, 2016, Pages

  Feaver, Ryan E ^a   Cole, Banumathi K ^a   Lawson, Mark J ^a   Hoang, Stephen A ^a   Marukian, Svetlana ^a   Blackman, Brett R ^b   Figler, Robert A ^a   Sanyal, Arun J ^c   Wamhoff, Brian R ^a   Dash, Ajit ^a  

^a HemoShear Therapeutics   (United States)

^b VL37 Inc ^*  (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85103867052     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.90954     Document Type: Article

References (68)

1. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci. 2005;50(1):171–180.
2. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343–1351.
3. Medina J, Fernández-Salazar LI, García-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care. 2004;27(8):2057–2066.
4. U.S. National Institutes of Health . https://clinicaltrials.gov. Accessed October 31, 2016.
5. Khetani SR, Berger DR, Ballinger KR, Davidson MD, Lin C, Ware BR. Microengineered liver tissues for drug testing. J Lab Autom. 2015;20(3):216–250.
6. Sanches SC, Ramalho LN, Augusto MJ, da Silva DM, Ramalho FS. Nonalcoholic steatohepatitis: a search for factual animal models. Biomed Res Int. 2015;2015:574832.
7. Dash A, et al. Hemodynamic flow improves rat hepatocyte morphology, function, and metabolic activity in vitro. Am J Physiol, Cell Physiol. 2013;304(11):C1053–C1063.
8. Terelius Y, et al. Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016;255:31–44.
9. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13(1):9–19.
10. Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des. 2013;19(29):5250–5269.
11. Hastings NE, Simmers MB, McDonald OG, Wamhoff BR, Blackman BR. Atherosclerosis-prone hemodynamics differentially regulates endothelial and smooth muscle cell phenotypes and promotes pro-inflammatory priming. Am J Physiol, Cell Physiol. 2007;293(6):C1824–C1833.
12. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88(1):125–172.
13. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723–737.
14. de Almeida IT, Cortez-Pinto H, Fidalgo G, Rodrigues D, Camilo ME. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr. 2002;21(3):219–223.
15. Chitturi S, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35(2):373–379.
16. Jensen LJ, et al. STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009;37(Database issue):D412–D416.
17. Ahrens M, et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab. 2013;18(2):296–302.
18. López-Vicario C, et al. Molecular interplay between Δ5/Δ6 desaturases and long-chain fatty acids in the pathogenesis of nonalcoholic steatohepatitis. Gut. 2014;63(2):344–355.
19. Straub BK, et al. Adipophilin/perilipin-2 as a lipid droplet-specific marker for metabolically active cells and diseases associated with metabolic dysregulation. Histopathology. 2013;62(4):617–631.
20. Puri P, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46(4):1081–1090.
21. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544–1560.
22. Ramnanan CJ, Edgerton DS, Cherrington AD. The role of insulin in the regulation of PEPCK and gluconeogenesis in vivo. US Endocrinol. 2009;5(1):34–39.
23. Diab DL, et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol. 2008;6(11):1249–1254.
24. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44(1):27–33.
25. Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2013;14(10):20704–20728.
26. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003;38(2):413–419.
27. Zhang X, et al. CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. J Hepatol. 2014;61(6):1365–1375.
28. Coulon S, et al. Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. Hepatology. 2013;57(5):1793–1805.
29. Cho SJ, et al. YKL-40 is a protective biomarker for fatty liver in World Trade Center particulate matter-exposed firefighters. J Mol Biomark Diagn. 2014;5.
30. Johansen JS, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol. 2000;32(6):911–920.
31. Johansen JS, Kirwan JR, Price PA, Sharif M. Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction. Scand J Rheumatol. 2001;30(5):297–304.
32. Kumagai E, et al. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep. 2016;6:35282.
33. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7):677–687.
34. Basaranoglu M, Basaranoglu G, Sentürk H. From fatty liver to fibrosis: a tale of “second hit”. World J Gastroenterol. 2013;19(8):1158–1165.
35. Neuschwander-Tetri BA, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–965.
36. Hirschfield GM, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148(4):751–61.e8.
37. Cole BK, et al. An in vitro cynomolgus vascular surrogate system for preclinical drug assessment and human translation. Arterioscler Thromb Vasc Biol. 2015;35(10):2185–2195.
38. Bhise NS, et al. A liver-on-a-chip platform with bioprinted hepatic spheroids. Biofabrication. 2016;8(1):014101.
39. Chen Q, Utech S, Chen D, Prodanovic R, Lin JM, Weitz DA. Controlled assembly of heterotypic cells in a core-shell scaffold: organ in a droplet. Lab Chip. 2016;16(8):1346–1349.
40. Esch MB, et al. Multi-cellular 3D human primary liver cell culture elevates metabolic activity under fluidic flow. Lab Chip. 2015;15(10):2269–2277.
41. Gori M, Simonelli MC, Giannitelli SM, Businaro L, Trombetta M, Rainer A. Investigating nonalcoholic fatty liver disease in a liver-on-a-chip microfluidic device. PLoS One. 2016;11(7):e0159729.
42. Ma X, et al. Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting. Proc Natl Acad Sci U S A. 2016;113(8):2206–2211.
43. Dash A, Figler RA, Sanyal AJ, Wamhoff BR. Drug-induced steatohepatitis [published online ahead of print October 19, 2016]. Expert Opin Drug Metb Toxicol. doi: 10.1080/17425255.2017.1246534.
44. LeCluyse EL, Witek RP, Andersen ME, Powers MJ. Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol. 2012;42(6):501–548.
45. Gorrell MD. Liver fibrosis: the hepatocyte revisited. Hepatology. 2007;46(5):1659–1661.
46. Serviddio G, et al. Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model. Eur J Clin Invest. 2008;38(4):245–252.
47. Gorden DL, et al. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J Lipid Res. 2015;56(3):722–736.
48. Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
49. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57:289–300.
50. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34(5):525–527.
51. Lander ES, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.
52. Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res. 2015;4:1521.
53. Kauffmann A, Gentleman R, Huber W. arrayQualityMetrics-a bioconductor package for quality assessment of microarray data. Bioinformatics. 2009;25(3):415–416.
54. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–140.
55. Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 2007;3(9):1724–1735.
56. Ashburner M, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25–29.
57. Croft D, et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 2014;42(Database issue):D472–D477.
58. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.
59. Nishimura D. Biotech Software and Internet Report. 2004;2(3):117–120. doi:10.1089/152791601750294344.
60. Schaefer CF, et al. PID: the Pathway Interaction Database. Nucleic Acids Res. 2009;37(Database issue):D674–D679.
61. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550.
62. Tarca AL, et al. A novel signaling pathway impact analysis. Bioinformatics. 2009;25(1):75–82.
63. Blondel V, Guillaume J-L, Lambiotte R, Lefebvre E. Fast unfolding of communities in large networks. J Stat Mech. 2008;P10008(3 Pt 2):doi:10.1088/1742-5468/2008/10/P10008.
64. Wu D, Lim E, Vaillant F, Asselin-Labat ML, Visvader JE, Smyth GK. ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics. 2010;26(17):2176–2182.
65. Jensen LJ, et al. STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009;37(Database issue):D412–D416.
66. Jacomy M, Venturini T, Heymann S, Bastian M. ForceAtlas2, a continuous graph layout algorithm for handy network visualization designed for the Gephi software. PLoS ONE. 2014;9(6):e98679.
67. Allison DB, et al. A mixture model approach for the analysis of microarray gene expression data. Comput Stat Data Anal. 2002;39:1–20.
68. Erickson S, Kim K, Allison DB. Composite hypothesis testing: an approach built on intersection-union tests and Bayesian posterior probabilities. In: Guerra R, Goldstetin DR, eds. Meta-anlaysis and combining information in genetics and genomics. London: Chapman and Hall/CRC; 2010:83–93.